Cue Biopharma, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Cue Biopharma, Inc. (CUE) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $883.84 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-03-21
- Cue Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $883.84K, a 70.88% decline from fiscal 2021.
- Cue Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $3.04M, a 27.77% decline from fiscal 2020.
- Cue Biopharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $4.20M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2022-12-31 | $883.84K 10-K · filed 2023-03-21 |
| 2021-12-31 | $3.04M 10-K · filed 2023-03-21 |
| 2020-12-31 | $4.20M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |